Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
Status:
Terminated
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Crescentic IgA nephropathy (CreIgAN) has a poor prognosis despite aggressive
immunosuppressive therapy. The efficacy of plasma exchange (PE) in CreIgAN is not well
defined. This study will evaluate the efficacy and safety of plasma exchange as adjunctive
therapy for severe crescentic IgA nephropathy compared to pulse methylprednisolone on a
background of oral prednisolone and cyclophosphamide in prevent kidney failure.